Q: Still dosing?That’s fantastic news, go rvx go!!
question tho... are we still dosing?
Last Study Visits (LSV) will commence immediately. All actively participating patients, still receiving the Investigational Product (IP) or statin, will be contacted to schedule visits to their particular site for a last visit or treatment visit.
Last visit or treatment visit? So we are still accumulating patient years and events? I don’t see any statements saying dosing stops. Is that how we get the additional events?
one thing I never fully grasped. Wasnt the trial designed for 250 events, then modified to 250+, so say 260. That’s 10 more events than designed, which is 10/250 = 4%, so if all those events fit in say one side, the good side, we have the ability to sway rrr by up to 4% in either direction?
if so, is that good trial design/standard clinical practice or an act of desperation? Hoping for the former but still something doesn’t seem right, hence fairly lukewarm market reception. Saw that nr this morning and it made me hurry up to get into work so I could watch the opening bell, and I honestly thought: how much are we going up today? Answer: not much! Better than nuthin obvi, but def not what I was hoping for, not even close!
Guess there won’t be any other inflection points until either top line or gasp, full data? What if a bland top line nr elicits the same market reaction? Maybe I need to reset my expectations, at least short term, or medium term the way we move!
anyways, make it happen!